Storage and handling
Store At Or Below 25 o C (77 o F), Excursions Permitted Up To 40 o C (104 o F)
Store At Or Below 25 o C (77 o F), Excursions Permitted Up To 40 o C (104 o F)
Carbadox . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.2% (10 g/lb)
Control of swine dysentery (vibrionic dysentery, bloody scours or hemorrhagic dysentery); control of bacterial swine enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis); increased rate of weight gain and improved feed efficiency in swine.
For use in the manufacture of complete swine feeds and/or swine protein supplement feeds only.
Certain components of animal feeds, including medicated premixes, possess properties that may be a potential health hazard or a source of personal discomfort to certain individuals who are exposed to them. Human exposure should, therefore, be minimized by observing the general industry standards for occupational health and safety.
Precautions such as the following should be considered: dust masks or respirators and protective clothing should be worn; dust-arresting equipment and adequate ventilation should be utilized; personal hygiene should be observed; wash before eating or leaving a work site; be alert for signs of allergic reactions–seek prompt medical treatment if such reactions are suspected.
Mixing and Use Directions
Indications for Use | Amount of Drug | lb of Mecadox® 10 per ton of Complete Feed |
Increased rate of weight gain and improved feed efficiency | 0.0011-0.00275% (10-25 g/ton) | 1.0-2.5 lb |
Control of swine dysentery (vibrionic dysentery, bloody scours or hemorrhagic dysentery); control of bacterial swine enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis); increased rate of weight gain and improved feed efficiency. | 0.0055% (50 g/ton) | 5.0 lb |
Protein Supplement
Mixing and Use Directions
Amount of Supplement per Ton of Complete Feed (lb) | lb of Mecadox® 10 per Ton of Protein Supplement | ||
Desired Level of Mecadox® in Complete Feed | |||
0.0055% (50 g/ton) | 0.00275% (25 g/ton) | 0.0011% (10 g/ton) | |
1000 667 500 250 100 75 50 40 20 | 10 15 20 40 100 133 200 250 500 | 5 7 10 20 50 67 100 125 250 | 2 3 4 8 20 27 40 50 100 |
Do not feed to swine within 42 days before slaughter.
Caution: Not for use in pregnant swine or swine intended for breeding purposes.
Do not mix in feeds containing bentonite.
NOT FOR HUMAN USE
RESTRICTED DRUG (CALIFORNIA) – USE ONLY AS DIRECTED
Store At Or Below 25oC (77oF), Excursions Permitted Up To 40oC (104oF)
See Back PANEL for Further Use Directions
Mecadox® is a Phibro Animal Health Corporation registered trademark for Carbadox
Phibro Animal Health Corporation, Teaneck, NJ 07666.
Net Weight 40 lb (18.2 kg)
7913000
101-9383-01
Approved by FDA under NADA # 041-061
Mecadox 10
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 66104-0006-0 | Mecadox | 22.6 kg in 1 BAG | POWDER | 22.6 | 9 | |
| 66104-0006-4 | Mecadox | 18.2 kg in 1 BAG | POWDER | 18.2 | 9 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 66104-0006 | MECADOX (CARBADOX) POWDER [PHIBRO ANIMAL HEALTH] | 9 | 2 package rows | 20231103_df49e55f-c531-4ac8-8dc2-58dbb3291cdf.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CARBADOX | ACTIVE INGREDIENT | M2X04R2E2Y | 5 | |
| CARBADOX | ACTIVE MOIETY | M2X04R2E2Y | 5 | |
| CALCIUM PROPIONATE | INACTIVE INGREDIENT | 8AI80040KW | 5 | |
| MINERAL OIL | INACTIVE INGREDIENT | T5L8T28FGP | 5 | |
| SOYBEAN | INACTIVE INGREDIENT | L7HT8F1ZOD | 5 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 66104-0006 | 66104-0006-4, 66104-0006-0 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CARBADOX | M2X04R2E2Y | ACTIB |
| MINERAL OIL | T5L8T28FGP | IACT |
| CALCIUM PROPIONATE | 8AI80040KW | IACT |
| SOYBEAN | L7HT8F1ZOD | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | PASTE / TOPICAL | 47.5 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, COATED / ORAL | 1.5 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUSPENSION / AURICULAR (OTIC) | 0.5 %w/v | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET / ORAL | 113.75 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CREAM / TOPICAL | 2772 mg | ||
| SOYBEAN | SOYBEAN | L7HT8F1ZOD | EMULSION / TOPICAL | 3 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OIL / TOPICAL | 43.29 %v/v | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | FILM / TRANSDERMAL | 11.42 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / VAGINAL | 30 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, CHEWABLE / ORAL | 6 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SPRAY / TOPICAL | 1379 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, FILM COATED / ORAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CAPSULE / ORAL | 120 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SYSTEM / TRANSDERMAL | 6.09 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SYSTEM / TOPICAL | 654.36 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / RECTAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | LOTION / TOPICAL | 1428 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | PASTE / DENTAL | 95 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SOAP / TOPICAL | 0.82 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | FILM, EXTENDED RELEASE / TRANSDERMAL | 34 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | DROPS / ORAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | GEL / TOPICAL | 2.5 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OINTMENT / AURICULAR (OTIC) | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CREAM / VAGINAL | 402 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUSPENSION / TOPICAL | 82 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OINTMENT / OPHTHALMIC | 59.5 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUSPENSION / OPHTHALMIC | 0.1 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OINTMENT / TOPICAL | 9938 mg | ||
| SOYBEAN | SOYBEAN | L7HT8F1ZOD | CAPSULE / ORAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, DELAYED RELEASE / ORAL | 5.67 mg |
Adverse event summaries are temporarily unavailable. Other product information remains available.